Tolerability and Bioavailability of BIBR 953 ZW and BIBR 1048 in Healthy Volunteers

Phase 1, randomised, double-blind trial of dabigatran etexilate oral solution in thromboembolism (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the plasma concentration-time curve extrapolated to infinity up to 48 hours, Area under the plasma concentration-time curve up to the last quantifiable plasma concentration up to 48 hours and 2 more. Started Jan 2001; status: completed.